查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030015

乾眼症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、產品類型、劑型、類型、分銷管道、地區和競爭格局分類，2021-2031年

Dry Eye Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Product Type, By Dosage Form, By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球乾眼症治療市場預計將從 2025 年的 65.9 億美元成長到 2031 年的 97.6 億美元，複合年成長率為 6.76%。

針對這種多因素疾病，治療方法包括多種藥物、醫療設備和外科手術，旨在緩解症狀、穩定淚膜並恢復眼表平衡。該市場的成長主要受全球乾眼症盛行率上升的驅動，而乾眼症的盛行率上升與人口老化和電子螢幕使用量的增加密切相關。此外，醫療專業人員和公眾對早期發現和治療重要性的認知不斷提高，也推動了該行業的發展。特別是，歐洲眼科學會 (ESO) 的估計表明，到 2025 年，約有 11.5% 的歐洲成年人將患有乾眼症，這凸顯了存在著大量需要有效治療的人群。

市場概覽
預測期 2027-2031
市場規模：2025年 65.9億美元
市場規模：2031年 97.6億美元
複合年成長率：2026-2031年 6.76%
成長最快的細分市場 缺水性乾眼症
最大的市場 北美洲

限制市場成長的主要障礙在於，目前仍難以開發出能夠實現持續緩解且有效針對所有亞型疾病通用的各種潛在病因的治療方法方法。這種限制往往導致患者不滿，因為目前的治療方法方法傾向於優先控制症狀而非根治。

市場促進因素

乾眼症在全球日益普遍，這主要源自於生活方式和人口結構的變化，也是推動市場擴張的主要動力。需要就醫的人數持續成長，尤其是老年人口不斷增加，他們更容易罹患眼表疾病。此外，工作和生活中過度使用電子螢幕也會加劇症狀，即使是年輕一代也不例外，導致眨眼次數減少和眼睛疲勞加劇。 2025年10月舉行的第43屆歐洲白內障和屈光手術學會（ESCRS）會議上發表的一項調查顯示，美國和歐洲有58%的人患有乾眼症。如此高的盛行率凸顯了對可靠治療方法的迫切需求，從而促進了新病例的診斷和持續治療。

另一個關鍵的成長要素是治療調查方法的持續進步，這些方法正在滿足未被滿足的需求並改善患者的治療效果。新型藥物和先進的給藥機制正在提高治療的療效和耐受性，從而提高患者的依從性並擴大市場。為了支持這一趨勢，愛爾康公司在2025年5月的新聞稿中宣布，用於治療乾眼症的開創性TRPM8受體促效劑TRYPTYR（Accortremon滴眼液）0.003%已獲得FDA核准。這些創新產品為眼科醫師提供了高度標靶和高效的治療選擇，從而推動了處方量的成長。這些新治療方法的商業性影響顯而易見，Tarsus Pharmaceuticals公司在2026年2月提交的10-K表格報告顯示，XDEMVY在2025年全年的淨銷售額為4.514億美元。

市場挑戰

全球乾眼症治療市場面臨嚴峻挑戰，因為現有治療方法無法確保長期緩解，也無法徹底解決該疾病各種變異體通用的根本病因。患者往往感到不滿，因為現有治療方法著重於緩解症狀而非真正治癒。該行業依賴暫時控制症狀而非永久性改善，使患者陷入持續且往往效果不佳的治療循環，阻礙了市場的進一步擴張。

由於這些不足，許多患者認為現有治療方法不佳或不適合自身特定情況。歐洲屈光和屈光手術學會 (ESCRS) 2025 年的數據顯示，只有 25% 的患者認為他們的乾眼症治療方案是真正個人化的，這印證了上述問題。這種不滿導致患者治療依從性降低，嘗試新治療方法的意願下降，並且不願意在無法保證永久改善的治療方案上花錢。最終，由於患者難以找到真正能夠改變病情進程或徹底治癒的治療方法，整個市場的成長受到限制。

市場趨勢

推動全球乾眼症治療發展的主要趨勢之一是以醫療設備為中心的治療方法不斷進步。這些尖端技術超越了傳統的眼藥水，能夠提供精準且持久的緩解，特別適用於瞼板腺功能障礙（MGD）患者，而瞼板腺功能障礙是蒸發性乾眼症的主要原因之一。這些設備利用熱脈衝和強烈脈衝光（IPL）等技術，從根本上改善腺體功能並穩定淚膜。例如，強生公司在2026年1月發布的報告顯示，其醫療技術與視覺部門2025年第四季的營收成長了8.9%，達到14億美元。這凸顯了包含醫療設備的眼科解決方案的成功。這一發展趨勢表明，人們越來越支持一種整體護理模式，即眼科專業人員在日常診療中結合使用先進的診斷和治療醫療設備。

此外，人們對防腐劑對眼表不良影響的認知不斷加深，促使消費者對不含防腐劑的藥物需求日益成長，這也對市場產生了顯著影響。慢性乾眼症患者通常需要長期治療，他們積極尋求替代傳統眼藥水的方案，因為傳統眼藥水通常含有苯扎氯銨（BAK）等成分，這些成分會加重刺激或損傷眼組織。提供單劑量管瓶和多劑量包裝的無防腐劑溶液大大提高了使用者的舒適度和依從性。為了佐證這一轉變，博士倫公司在2026年2月的財報電話會議上報告稱，其專注於無添加劑產品的消費者乾眼症業務在2025年第四季度實現了1.16億美元的銷售額。這一強勁的業績表明，消費者對更安全、刺激性更小的治療方法的需求不斷成長，各公司正在處方藥和非處方藥市場拓展其無添加劑產品線。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球乾眼症治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（蒸發性乾眼症、脫水性乾眼症）
    • 產品類型（Cyclosporine、局部類固醇、人工淚液、淚小管栓塞、其他）
    • 劑型（凝膠、眼藥水、膠囊/錠劑、眼藥水、軟膏）
    • 依類型（處方藥與非處方藥）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美乾眼症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲乾眼症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區乾眼症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲乾眼症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲乾眼症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球乾眼症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Sun Pharmaceuticals Industries Limited
  • Santen Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • Alcon Inc.
  • GlaxoSmithKline plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 14428

The Global market for Dry Eye Syndrome treatments is anticipated to expand from USD 6.59 billion in 2025 to USD 9.76 billion by 2031, reflecting a compound annual growth rate of 6.76%. Therapeutic options for this multifactorial condition include various pharmaceuticals, medical devices, and surgical methods aimed at easing symptoms, stabilizing the tear film, and restoring balance to the ocular surface. This market growth is primarily fueled by the rising worldwide incidence of dry eye, which is closely tied to aging demographics and growing digital screen usage. Additionally, increased recognition of the importance of early detection and treatment among medical professionals and the general public is propelling the industry forward. Notably, the European Society of Ophthalmology estimated that approximately 11.5% of European adults experienced dry eye disease in 2025, highlighting a vast demographic in need of effective treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.59 Billion
Market Size 2031USD 9.76 Billion
CAGR 2026-20316.76%
Fastest Growing SegmentAqueous Deficient Dry Eye Syndrome
Largest MarketNorth America

A major hurdle limiting market growth is the ongoing difficulty in creating therapies that deliver lasting remission or effectively target the varied underlying causes across all subtypes of the disease. This limitation often results in patient frustration, as current approaches typically emphasize managing symptoms rather than providing definitive cures.

Market Driver

The rising worldwide incidence of dry eye syndrome, driven by changing lifestyles and demographics, serves as a major engine for market expansion. An expanding elderly population, which is especially prone to ocular surface disorders, continues to widen the demographic needing medical care. Additionally, the extensive use of digital screens for both professional and personal activities leads to less frequent blinking and greater eye strain, worsening symptoms even in younger individuals. Research shared at the 43rd Congress of the European Society of Cataract and Refractive Surgeons in October 2025 revealed that 58% of people in the US and Europe experienced dry eye symptoms. This high prevalence highlights the urgent demand for reliable treatments, stimulating both new diagnoses and continuous care requirements.

Another significant growth driver is the continuous progress in treatment methodologies, which helps fulfill unmet clinical needs and boosts patient results. New classes of medications and advanced delivery mechanisms improve both the effectiveness and tolerability of treatments, thereby encouraging better patient compliance and broadening the market. Highlighting this trend, an Alcon press release from May 2025 announced FDA approval for TRYPTYR (acoltremon ophthalmic solution) 0.003%, a pioneering TRPM8 receptor agonist for dry eye disease. These innovations equip eye care specialists with highly focused, efficient resources that drive up prescription volumes. The commercial impact of these novel therapies is evident, as shown in Tarsus Pharmaceuticals' February 2026 Form 10-K, which reported $451.4 million in net sales for XDEMVY throughout 2025.

Market Challenge

The worldwide market for Dry Eye Syndrome treatments encounters a major obstacle regarding the inability of current therapies to ensure prolonged remission or fully resolve the distinct root causes across different disease variations. Available interventions primarily prioritize alleviating symptoms instead of providing a true cure, which often leaves patients feeling dissatisfied. The industry's dependence on temporary symptom management, rather than permanent improvement, hinders broader market expansion by trapping patients in ongoing, yet frequently inadequate, treatment loops.

As a result of these shortcomings, many patients view existing treatments as inadequate or poorly customized to their unique circumstances. Demonstrating this issue, data from the European Society of Cataract and Refractive Surgeons in 2025 indicated that a mere 25% of individuals believed their dry eye regimen was suitably personalized. Such dissatisfaction leads to lower treatment compliance, less willingness to try novel therapies, and a reluctance to spend money on options that fail to guarantee permanent relief. Ultimately, overall market growth is restricted because patients struggle to find interventions that genuinely alter the disease course or offer total healing.

Market Trends

A major trend shaping the global dry eye treatment landscape is the ongoing advancement of device-centric therapies. Moving past conventional eye drops, these modern innovations provide precise and long-lasting relief, especially for individuals suffering from meibomian gland dysfunction (MGD), the primary culprit behind evaporative dry eye. Utilizing technologies like thermal pulsation and intense pulsed light (IPL), these devices target the root causes to enhance gland performance and stabilize the tear film. Illustrating this momentum, Johnson & Johnson reported in January 2026 that its MedTech vision division saw an 8.9% increase in its fourth-quarter 2025 financial results, achieving $1.4 billion and highlighting the success of device-inclusive ophthalmic solutions. This evolution points to a growing embrace of holistic care models where eye care professionals combine advanced diagnostic and therapeutic devices in their daily practice.

Additionally, the market is heavily influenced by a rising consumer shift toward preservative-free medications, spurred by a better understanding of how preservatives can harm the surface of the eye. Individuals managing chronic dry eye often depend on long-term care and actively seek substitutes for conventional drops that use ingredients like benzalkonium chloride (BAK), which can worsen irritation and damage ocular tissues. Offering preservative-free solutions in both single-use vials and multi-dose containers has significantly improved user comfort and compliance. Highlighting this shift, Bausch + Lomb's February 2026 earnings call noted that its consumer dry eye division, featuring preservative-free items, achieved $116 million in fourth-quarter 2025 revenue. This robust financial outcome emphasizes the escalating need for safer, milder treatments, prompting companies to broaden their preservative-free portfolios in both prescription and over-the-counter markets.

Key Market Players

  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Sun Pharmaceuticals Industries Limited
  • Santen Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • Alcon Inc.
  • GlaxoSmithKline plc

Report Scope

In this report, the Global Dry Eye Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication

  • Evaporative Dry Eye Syndrome
  • Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Others

Dry Eye Syndrome Treatment Market, By Dosage Form

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

Dry Eye Syndrome Treatment Market, By Type

  • Prescription
  • Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dry Eye Syndrome Treatment Market.

Available Customizations:

Global Dry Eye Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dry Eye Syndrome Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome)
    • 5.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
    • 5.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
    • 5.2.4. By Type (Prescription v/s Over The Counter)
    • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Dry Eye Syndrome Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Product Type
    • 6.2.3. By Dosage Form
    • 6.2.4. By Type
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dry Eye Syndrome Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By Dosage Form
        • 6.3.1.2.4. By Type
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By Dosage Form
        • 6.3.2.2.4. By Type
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By Dosage Form
        • 6.3.3.2.4. By Type
        • 6.3.3.2.5. By Distribution Channel

7. Europe Dry Eye Syndrome Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product Type
    • 7.2.3. By Dosage Form
    • 7.2.4. By Type
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dry Eye Syndrome Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Dosage Form
        • 7.3.1.2.4. By Type
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. France Dry Eye Syndrome Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Dosage Form
        • 7.3.2.2.4. By Type
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Dosage Form
        • 7.3.3.2.4. By Type
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By Dosage Form
        • 7.3.4.2.4. By Type
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By Dosage Form
        • 7.3.5.2.4. By Type
        • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Dry Eye Syndrome Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product Type
    • 8.2.3. By Dosage Form
    • 8.2.4. By Type
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dry Eye Syndrome Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Dosage Form
        • 8.3.1.2.4. By Type
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Dry Eye Syndrome Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Dosage Form
        • 8.3.2.2.4. By Type
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Dosage Form
        • 8.3.3.2.4. By Type
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Dosage Form
        • 8.3.4.2.4. By Type
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Dosage Form
        • 8.3.5.2.4. By Type
        • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product Type
    • 9.2.3. By Dosage Form
    • 9.2.4. By Type
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Dosage Form
        • 9.3.1.2.4. By Type
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. UAE Dry Eye Syndrome Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Dosage Form
        • 9.3.2.2.4. By Type
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. South Africa Dry Eye Syndrome Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Dosage Form
        • 9.3.3.2.4. By Type
        • 9.3.3.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product Type
    • 10.2.3. By Dosage Form
    • 10.2.4. By Type
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Dosage Form
        • 10.3.1.2.4. By Type
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Colombia Dry Eye Syndrome Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Dosage Form
        • 10.3.2.2.4. By Type
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Argentina Dry Eye Syndrome Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Dosage Form
        • 10.3.3.2.4. By Type
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dry Eye Syndrome Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Johnson & Johnson Services, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie Inc.
  • 15.3. Bausch Health Companies Inc.
  • 15.4. Novartis AG
  • 15.5. Sun Pharmaceuticals Industries Limited
  • 15.6. Santen Pharmaceutical Co., Ltd.
  • 15.7. Otsuka Pharmaceutical Co., Ltd.
  • 15.8. Oyster Point Pharma, Inc.
  • 15.9. Alcon Inc.
  • 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer